Theus-Steinmann, C.; Schelling, G.; Heesen, P.; Breitenstein, S.; Scaglioni, M. F.; Fuchs, B. How Is the Spectrum of Sarcoma Surgery Assessed? Cancers, 2023, 15, 1305. https://doi.org/10.3390/cancers15041305.
Theus-Steinmann, C.; Schelling, G.; Heesen, P.; Breitenstein, S.; Scaglioni, M. F.; Fuchs, B. How Is the Spectrum of Sarcoma Surgery Assessed? Cancers, 2023, 15, 1305. https://doi.org/10.3390/cancers15041305.
Theus-Steinmann, C.; Schelling, G.; Heesen, P.; Breitenstein, S.; Scaglioni, M. F.; Fuchs, B. How Is the Spectrum of Sarcoma Surgery Assessed? Cancers, 2023, 15, 1305. https://doi.org/10.3390/cancers15041305.
Theus-Steinmann, C.; Schelling, G.; Heesen, P.; Breitenstein, S.; Scaglioni, M. F.; Fuchs, B. How Is the Spectrum of Sarcoma Surgery Assessed? Cancers, 2023, 15, 1305. https://doi.org/10.3390/cancers15041305.
Abstract
Purpose: To meet the challenges of the precision medicine era, quality assessment of shared sarcoma care becomes pivotal. The MDT approach is the most important parameter for succesfull outcome. Because of all MDTs disciplines surgery is the key step to render sarcoma patients disease free, defining the spectrum of a sarcoma surgeon is critical. To the best of the authors knowledge, a comprehensive interoperable digital platform to assess the scope of sarcoma surgery and the experience of a sarcoma surgeon in its full complexity is lacking. Methods: A web-based real-world data (RWD) registry on sarcoma surgery has been created to assess the clinical exposure, tumor characteristics, and surgical settings and techniques applied for both resections and reconstructions of sarcomas and thereby the surgical exposure of an individual surgeon over time. Results: During 10 years, there were 723 sarcoma board/MDT meetings discussing 3130 patients. A total of 1094 patients underwent 1250 surgical interventions on mesenchymal tumors by one single sarcoma surgeon. These included 615 deep soft tissue tumors (197 benign, 102 intermediate, 281 malignant, 27 simulator, 7 metastasis, 1 blood), 116 superficial soft tissue tumors (45 benign, 12 intermediate, 40 malignant, 18 simulator, 1 blood) and 519 bone tumors (129 benign, 112 intermediate, 182 malignant, 18 simulator, 46 metastasis, 14 blood and 18 sequelae of 1st treatment). Detailed types of resections and reconstructions were analyzed. Conclusion: A web-based RWD sarcoma surgeon registry with transparent real-time descriptive analytics is feasible and enables large scale definition of the surgical complexity and ultimately quality of sarcoma care.
Keywords
sarcoma; multidisciplinary team / MDT; sarcoma surgery; orthopedic oncology; real-world data registry; exposure; experience
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
